Free trial offer

Patients who are new to therapy with BOSULIF may be eligible for a free 30-day trial offer. Terms and Conditions apply; see below.
For more information on the voucher program and to obtain a 30-day free trial offer, please contact Pfizer Oncology Together at
or your local Pfizer Oncology representative.
Terms and Conditions for Trial Voucher Program
By enrolling in the 30-day trial voucher offer for BOSULIF, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
1. Voucher is valid for a 30-day supply of BOSULIF.
2. Only new patients may use this voucher. By redeeming this voucher, you certify that you are not currently using BOSULIF.
3. An original voucher and a valid prescription must be presented to the pharmacy.
4. The voucher will be accepted only at participating pharmacies.
5. You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
6. You must be 18 years of age or older to redeem this voucher.
7. This voucher is not valid where prohibited by law.
8. This voucher cannot be combined with any other savings, free trial or similar offer for the specified prescription.
9. This free trial voucher is not health insurance.
10. Offer good only in the U.S. and Puerto Rico.
11. No purchase is necessary.
12. Patients have no obligation to continue to use BOSULIF.
13. Pfizer reserves the right to rescind, revoke or amend this offer without notice.
14. This voucher expires 12/31/2021.
For more information, call 1-877-744-5675, contact Pfizer Inc. at 235 East 42nd Street, New York, NY 10017, or visit
Ph+=Philadelphia chromosome–positive.
BOSULIF Prescribing Information. New York, NY: Pfizer Inc.